Do You Know... Cocaine
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Methylphenidate Hydrochloride
Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications. -
Comparison of the Inhibitory and Excitatory Effects of ADHD Medications Methylphenidate and Atomoxetine on Motor Cortex
Neuropsychopharmacology (2006) 31, 442–449 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Comparison of the Inhibitory and Excitatory Effects of ADHD Medications Methylphenidate and Atomoxetine on Motor Cortex ,1 2 3 1 1 4 Donald L Gilbert* , Keith R Ridel , Floyd R Sallee , Jie Zhang , Tara D Lipps and Eric M Wassermann 1 2 Division of Neurology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA; University of Cincinnati 3 4 School of Medicine, Cincinnati, OH, USA; Division of Psychiatry, University of Cincinnati, Cincinnati, OH, USA; Brain Stimulation Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA Stimulant and norepinephrine (NE) reuptake inhibitor medications have different effects at the neuronal level, but both reduce symptoms of attention deficit hyperactivity disorder (ADHD). To understand their common physiologic effects and thereby gain insight into the neurobiology of ADHD treatment, we compared the effects of the stimulant methylphenidate (MPH) and NE uptake inhibitor atomoxetine (ATX) on inhibitory and excitatory processes in human cortex. Nine healthy, right-handed adults were given a single, oral dose of 30 mg MPH and 60 mg ATX at visits separated by 1 week in a randomized, double-blind crossover trial. We used paired and single transcranial magnetic stimulation (TMS) of motor cortex to measure conditioned and unconditioned motor-evoked potential amplitudes at inhibitory (3 ms) and facilitatory (10 ms) interstimulus intervals (ISI) before and after drug administration. Data were analyzed with repeated measures, mixed model regression. We also analyzed our findings and the published literature with meta-analysis software to estimate treatment effects of stimulants and NE reuptake inhibitors on these TMS measures. -
Methylphenidate Amplifies the Potency and Reinforcing Effects Of
ARTICLE Received 1 Aug 2013 | Accepted 7 Oct 2013 | Published 5 Nov 2013 DOI: 10.1038/ncomms3720 Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression Erin S. Calipari1, Mark J. Ferris1, Ali Salahpour2, Marc G. Caron3 & Sara R. Jones1 Methylphenidate (MPH) is commonly diverted for recreational use, but the neurobiological consequences of exposure to MPH at high, abused doses are not well defined. Here we show that MPH self-administration in rats increases dopamine transporter (DAT) levels and enhances the potency of MPH and amphetamine on dopamine responses and drug-seeking behaviours, without altering cocaine effects. Genetic overexpression of the DAT in mice mimics these effects, confirming that MPH self-administration-induced increases in DAT levels are sufficient to induce the changes. Further, this work outlines a basic mechanism by which increases in DAT levels, regardless of how they occur, are capable of increasing the rewarding and reinforcing effects of select psychostimulant drugs, and suggests that indivi- duals with elevated DAT levels, such as ADHD sufferers, may be more susceptible to the addictive effects of amphetamine-like drugs. 1 Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. 2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada M5S1A8. 3 Department of Cell Biology, Medicine and Neurobiology, Duke University Medical Center, Durham, North Carolina 27710, USA. Correspondence and requests for materials should be addressed to S.R.J. (email: [email protected]). NATURE COMMUNICATIONS | 4:2720 | DOI: 10.1038/ncomms3720 | www.nature.com/naturecommunications 1 & 2013 Macmillan Publishers Limited. -
Interactions Between Ethanol and Cocaine, Amphetamine, Or MDMA in the Rat: Thermoregulatory and Locomotor Effects
Psychopharmacology DOI 10.1007/s00213-007-1007-5 ORIGINAL INVESTIGATION Interactions between ethanol and cocaine, amphetamine, or MDMA in the rat: thermoregulatory and locomotor effects Sami Ben Hamida & Erin Plute & Brigitte Cosquer & Christian Kelche & Byron C. Jones & Jean-Christophe Cassel Received: 22 May 2007 /Accepted: 29 October 2007 # Springer-Verlag 2007 Abstract duced by EtOH alone. Conversely, EtOH attenuated Rationale (±)-3,4-methylenedioxymethamphetamine MDMA-related hyperthermia, an effect increasing across (MDMA, ecstasy) is often taken recreationally with ethanol treatment days. These results demonstrate that the interac- (EtOH). In rats, EtOH may potentiate MDMA-induced tion between MDMA and EtOH may be different from the hyperactivity, but attenuate hyperthermia. interaction between EtOH and AMPH or COCA. Objective Experiment 1 compared the interactions between Conclusion Because of potential health-related consequen- EtOH (1.5 g/kg) and MDMA (6.6 mg/kg) with EtOH + ces of such polydrug misuse, it is worth identifying the cocaine (COCA; 10 mg/kg) and EtOH + amphetamine mechanisms underlying these interactions, especially be- (AMPH; 1 mg/kg) on locomotor activity and thermoregu- tween EtOH and MDMA. Given the different affinity lation. Experiment 2 used a weaker dose of MDMA profiles of the three drugs for serotonin, dopamine, and (3.3 mg/kg) and larger doses of COCA (20 mg/kg) and norepinephrine transporters, our results appear compatible AMPH (2 mg/kg). with the possibility of an important role of serotonin in at Materials and methods Drug treatments were administered least the EtOH-induced potentiation of MDMA-induced on four occasions (2, 5, and 2 days apart, respectively; hyperlocomotion. -
Synthetic Cathinones ("Bath Salts")
Synthetic Cathinones ("Bath Salts") What are synthetic cathinones? Synthetic cathinones, more commonly known as "bath salts," are synthetic (human- made) drugs chemically related to cathinone, a stimulant found in the khat plant. Khat is a shrub grown in East Africa and southern Arabia, and people sometimes chew its leaves for their mild stimulant effects. Synthetic variants of cathinone can be much stronger than the natural product and, in some cases, very dangerous (Baumann, 2014). In Name Only Synthetic cathinone products Synthetic cathinones are marketed as cheap marketed as "bath salts" should substitutes for other stimulants such as not be confused with products methamphetamine and cocaine, and products such as Epsom salts that people sold as Molly (MDMA) often contain synthetic use during bathing. These cathinones instead (s ee "Synthetic Cathinones bathing products have no mind- and Molly" on page 3). altering ingredients. Synthetic cathinones usually take the form of a white or brown crystal-like powder and are sold in small plastic or foil packages labeled "not for human consumption." Also sometimes labeled as "plant food," "jewelry cleaner," or "phone screen cleaner," people can buy them online and in drug paraphernalia stores under a variety of brand names, which include: Flakka Bloom Cloud Nine Lunar Wave Vanilla Sky White Lightning Scarface Image courtesy of www.dea.gov/pr/multimedia- library/image-gallery/bath-salts/bath-salts04.jpg Synthetic Cathinones • January 2016 • Page 1 How do people use synthetic cathinones? People typically swallow, snort, smoke, or inject synthetic cathinones. How do synthetic cathinones affect the brain? Much is still unknown about how synthetic cathinones affect the human brain. -
A User's Guide to Methamphetamine
A USER’S GUIDE TO METHAMPHETAMINE A self-help guide to reduce harm for people who use methamphetamine 1st Edition, March 2017 Acknowledgements This booklet was adapted from an original publication created by The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. This information does not constitute medical advice. Please seek the immediate help of a qualified medical practitioner about any personal health concerns. This booklet is being distributed for information purposes only. In the current state of crisis related to crystal methamphetamine, this booklet is intended as a guide to reduce harm for people who use methamphetamine. It lists the most common features of methamphetamine use, ways to reduce harm associated with the use of meth, and strategies for cutting down and quitting. The best way to avoid problems with drugs is to not use them. We are grateful for the contributions of the Integrated Drug Strategies in Waterloo Region and Guelph Wellington, in particular the leadership of Adrienne Crowder and Lindsay Sprague. Don Roth, Kerry Manthenga, Shirley Hilton, and our community review team provided great support and helpful edits. Marcey Gray provided exemplary skill on the design, images and editing, with final expert assistance from Arkay Design and Print. We are thankful for the financial support to print copies from the Waterloo-Wellington Human Services and Justice Coordinating Committee. For more information please contact: Wellington Guelph Drug Strategy www.wgdrugstrategy.ca Waterloo Region Integrated Drugs Strategy www.waterlooregiondrugstrategy.ca Circulated with the support of: WaterlooRegion Integrated Drugs Strategy WaterlooRegion Integrated Drugs Strategy The best way to avoid problems with drugs is to not use them. -
The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines World Health Organization F10 - F19 Mental and behavioural disorders due to psychoactive substance use Overview of this block F10. – Mental and behavioural disorders due to use of alcohol F11. – Mental and behavioural disorders due to use of opioids F12. – Mental and behavioural disorders due to use of cannabinoids F13. – Mental and behavioural disorders due to use of sedative hypnotics F14. – Mental and behavioural disorders due to use of cocaine F15. – Mental and behavioural disorders due to use of other stimulants, including caffeine F16. – Mental and behavioural disorders due to use of hallucinogens F17. – Mental and behavioural disorders due to use of tobacco F18. – Mental and behavioural disorders due to use of volatile solvents F19. – Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances Four- and five-character codes may be used to specify the clinical conditions, as follows: F1x.0 Acute intoxication .00 Uncomplicated .01 With trauma or other bodily injury .02 With other medical complications .03 With delirium .04 With perceptual distortions .05 With coma .06 With convulsions .07 Pathological intoxication F1x.1 Harmful use F1x.2 Dependence syndrome .20 Currently abstinent .21 Currently abstinent, but in a protected environment .22 Currently on a clinically supervised maintenance or replacement regime [controlled dependence] .23 Currently abstinent, but receiving treatment with -
Booklet 4 Stimulants Preface
4 STIMULANTS 4 STIMULANTS 2019 2019 © United Nations, June 2019. All rights reserved worldwide. ISBN: 978-92-1-148314-7 eISBN: 978-92-1-004174-4 United Nations publication, Sales No. E.19.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: www.unodc.org/wdr2019 PREFACE The findings of this year’s World Drug Report fill in same time clamping down on organized crime and and further complicate the global picture of drug trafficking. -
What Every Clinician Should Know Before Starting a Patient on Meds
CARING FOR CHILDREN WITH ADHD: A RESOURCE TOOLKIT FOR CLINICIANS, 2ND EDITION Basic Facts: What Every Clinician Should Know Before Starting a Patient on Medication Studies have shown that treatment for attention-deficit/ • If you reach the maximum recommended dose without • hyperactivity disorder (ADHD) with medication is effective in noticeable improvement in symptoms, try a different stimulant treating the symptoms of ADHD alone or in combination with medication class. Approximately 80% of children will respond to behavioral interventions. at least 1 of the 2 stimulant classes tried. • Stimulant medications also improve academic productivity but • When changing medications, be careful about the dose not cognitive abilities or academic skills. equivalence of different stimulant medication classes; in general, equivalent doses for dexmethylphenidate and Stimulants can help reduce oppositional, aggressive, impulsive, • amphetamine-based stimulants are approximately half of a and delinquent behaviors in some children. methylphenidate dose. Several types of medications are Food and Drug Administration Non-stimulant medications may require 2 or more weeks to see • (FDA)-approved for the treatment of ADHD. • effects, so you should titrate up more slowly than you would • Stimulant medications: methylphenidate, dexmethylphenidate, for stimulant medications. Obtaining follow-up rating scales is dextroamphetamine, mixed amphetamine salts, even more important than for stimulant medications because lisdexamfetamine changes are more gradual. • Non-stimulant medications: atomoxetine, and extended-release • Managing side effects effectively can improve adherence to and guanfacine and clonidine satisfaction with stimulant medications. When choosing which stimulant and dose to start first, consider • Common side effects to discuss with families include • stomachache, headache, decreased appetite, sleep problems, Family preference and experience with the medication, including • and behavioral rebound. -
A Brief Overview of Psychiatric Pharmacotherapy
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures • Some medications discussed are not approved by the FDA for use in the population discussed/described. • Some medications discussed are not approved by the FDA for use in the manner discussed/described. • Co-Owner: – PrairieCare and PrairieCare Medical Group – Catch LLC Disclaimer The contents of this handout are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical or psychiatric condition. Never disregard professional/medical advice or delay in seeking it because of something you have read in this handout. Material in this handout may be copyrighted by the author or by third parties; reasonable efforts have been made to give attribution where appropriate. Caveat Regarding the Role of Medication… Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. http://medicineworld.org/images/news-blogs/brain-700997.jpg Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. Neurotransmitter Receptor Source: National Institute on Drug Abuse Common Diagnoses and Associated Medications • Psychotic Disorders – Antipsychotics • Bipolar Disorders – Mood Stabilizers, Antipsychotics, & Antidepressants • Depressive Disorders – Antidepressants • Anxiety Disorders – Antidepressants & Anxiolytics • Attention Deficit Hyperactivity Disorder – Stimulants, Antidepressants, 2-Adrenergic Agents, & Strattera Classes of Medications • Anti-depressants • Stimulants and non-stimulant alternatives • Anti-psychotics (a.k.a. -
Commonly Used Drugs
Commonly Used Drugs Many drugs can alter a person’s thinking and judgment, and can lead to health risks, including addiction, drugged driving, infectious disease, and adverse effects on pregnancy. Information on commonly used drugs with the potential for misuse or addiction can be found here. For information about treatment options for substance use disorders, see NIDA’s Treatment pages. For drug use trends, see our Trends and Statistics page. For the most up-to-date slang terms, please see Slang Terms and Code Words: A Reference for Law Enforcement Personnel (DEA, PDF, 1MB). The following drugs are included in this resource: ➢ Alcohol ➢ Methamphetamine ➢ Ayahuasca ➢ Over-the-Counter Medicines--Dextromethorphan ➢ Central Nervous System Depressants (DXM) ➢ Cocaine ➢ Over-the-Counter Medicines--Loperamide ➢ DMT ➢ PCP ➢ GHB ➢ Prescription Opioids ➢ Hallucinogens ➢ Prescription Stimulants ➢ Heroin ➢ Psilocybin ➢ Inhalants ➢ Rohypnol® (Flunitrazepam) ➢ Ketamine ➢ Salvia ➢ Khat ➢ Steroids (Anabolic) ➢ Kratom ➢ Synthetic Cannabinoids ➢ LSD ➢ Synthetic Cathinones ("Bath Salts") ➢ Marijuana (Cannabis) ➢ Tobacco/Nicotine ➢ MDMA (Ecstasy/Molly) ➢ Mescaline (Peyote) **Drugs are classified into five distinct categories or schedules “depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential.” More information and the most up-to-date scheduling information can be found on the Drug Enforcement Administration’s website. June 2020 Alcohol People drink to socialize, celebrate, and relax. Alcohol often has a strong effect on people—and throughout history, people have struggled to understand and manage alcohol’s power. Why does alcohol cause people to act and feel differently? How much is too much? Why do some people become addicted while others do not? The National Institute on Alcohol Abuse and Alcoholism is researching the answers to these and many other questions about alcohol. -
Section 124.401 (31, 2) §124.401, CONTROLLED SUBSTANCES 2
1 CONTROLLED SUBSTANCES, §124.401 124.401 Prohibited acts — manufacture, delivery, possession — counterfeit substances, simulated controlled substances, imitation controlled substances — penalties. 1. Except as authorized by this chapter, it is unlawful for any person to manufacture, deliver, or possess with the intent to manufacture or deliver, a controlled substance, a counterfeit substance, a simulated controlled substance, or an imitation controlled substance, or to act with, enter into a common scheme or design with, or conspire with one or more other persons to manufacture, deliver, or possess with the intent to manufacture or deliver a controlled substance, a counterfeit substance, a simulated controlled substance, or an imitation controlled substance. a. Violation of this subsection, with respect to the following controlled substances, counterfeit substances, simulated controlled substances, or imitation controlled substances, is a class “B” felony, and notwithstanding section 902.9, subsection 1, paragraph “b”, shall be punished by confinement for no more than fifty years and a fine of not more than one million dollars: (1) More than one kilogram of a mixture or substance containing a detectable amount of heroin. (2) More than five hundred grams of a mixture or substance containing a detectable amount of any of the following: (a) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine and their salts have been removed. (b) Cocaine, its salts, optical and geometric isomers, or salts of isomers. (c) Ecgonine, its derivatives, their salts, isomers, or salts of isomers. (d) Any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subparagraph divisions (a) through (c).